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CASE REPORT
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Abstract
Congenital prothrombin deficiency is an extremely rare, autosomal recessive bleeding disorder with a prevalence of 1 in 2 million individuals. Here, we report a case of
congenital prothrombin deficiency with two concurrent mutations in the prothrombin
gene (F2), affecting the heavy B chain. The patient presented with a history of multiple bleeding events in his youth that are mostly trauma associated, with a family
history of prothrombin deficiency. Laboratory analysis showed a prolonged activated
partial thromboplastin time and a prothrombin activity level of 5%. Genetic analysis of
the F2 gene identified two heterozygous variants; one is a previously reported pathogenic deletion (c.1814_1815del; p.His605Argfs*13), and the other is a novel missense
variant (c.1147C>T; p.Arg383Trp). In silico analysis predicted that p.Arg383Trp is likely
to be disease causing, as it affects one of the anion-binding exosites-I of the B chain.
This case highlights the significance of molecular findings in confirming the diagnosis
of patients with congenital prothrombin deficiency.
KEYWORDS

bleeding disorder, dysprothrombinemia, hypoprothrombinemia, prothrombin deficiency,
prothrombin mutation

Essentials
• Congenital prothrombin deficiency is a rare bleeding disorder.
• We report a patient with congenital prothrombin deficiency.
• We identified two genetic variants (one novel) in the prothrombin gene.
• This case highlights the relevance of molecular analysis in rare bleeding disorders.
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I NTRO D U C TI O N

can be classified as hypoprothrombinemia or “true deficiency” (type
1), dysprothrombinemia (type 2), or combined forms. A new classifi-

Congenital prothrombin deficiency is a rare, autosomal recessive

cation adds a new category: dysprothrombinemia without bleeding

bleeding disorder with a prevalence of 1 in 2 million individuals.1 It

but with thrombosis (type 3). 2 A low level of prothrombin activity
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is always detectable, as complete prothrombin deficiency is incom-

in accordance with our institutional guidelines, DNA was isolated

patible with life. Although a prothrombin coagulant activity <10% is

from peripheral blood leukocytes using standard methods with the

usually associated with severe bleeding manifestations3 (including

MagNA Pure system (Roche Diagnostics, Laval, QC, Canada). The

mucosal bleeding, subcutaneous and muscle hematoma, and pro-

DNA sample was quantified by measuring absorbance with a DTX

longed bleeding episodes following injury), there is a discrepancy

880 Multimode Detector (Beckman Coulter, Brea, CA, USA). Coding

between the bleeding severity and the observed values of coagula-

regions and the flanking intronic regions (up to ±20 base pairs) of the

tion tests.1 Patients with prothrombin deficiency are either homozy-

prothrombin gene were polymerase chain reaction (PCR) amplified.

gous or compound heterozygous for mutations in the F2 gene, also

Purified PCR products were sequenced using the BigDye Terminator

known as prothrombin. Patients with true deficiency (with homozy-

version 1.1 cycle sequencing kit (Life Technologies, Rockville, MD,

gous mutations or compound heterozygous mutation) have <10%

USA) and subjected to capillary electrophoresis on an ABI 3730 (Life

normal prothrombin levels. Heterozygous mutation carriers usually

Technologies). Chromatograms obtained after sequencing were ana-

have prothrombin levels ranging from 30% to 60%, and >70% levels

lyzed with Mutation Surveyor version 4.0.7 software (SoftGenetics,

are reported as normal.1 To the best of our knowledge, <50 cases of

LLC, State College, PA, USA). Molecular analysis and variant clas-

hypoprothrombinemia or dysprothrombinemia have been character-

sification were performed by a clinical molecular geneticist at the

ized from a molecular genetic perspective. 2,4–6 Herein, we report a

Molecular Genetics Laboratory of our institution. Variants were in-

case of congenital prothrombin deficiency resulting from two con-

terpreted on the basis of the American College of Medical Genetics

current mutations in the F2 gene, affecting the heavy B chain.

guidelines.7 In silico variant analysis was performed using the Alamut
Visual Software (https://www.interactive-biosof tware.com/alamu
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C A S E R E P O RT

t-visual/) including Polymorphism Phenotyping-28 (PolyPhen-2,
http://genetics.bwh.harvard.edu/pph2/ index.shtml), SIFT9 (http://
sift.jcvi.org/), and Mutation Taster10 (http://www.mutationtaster.

A 30-year-old man, originally from Iran, was referred to our clinic

org/).

with a history of prothrombin deficiency, which was documented
during childhood. The patient reported multiple bleeding events
in his youth related to trauma, consisting of hemarthrosis of both

3
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DISCUSSION

knees and right elbow. The average frequency of events was one
to two bleeds per year, needing treatment with self-a dministered

Prothrombin (factor II) is a vitamin K–dependent glycoprotein en-

FEIBA (factor VIII inhibitor bypassing activity) and/or tranexamic

coded by a gene on chromosome 11p11-q1212 in the centromere re-

acid. His worst bleeding episode occurred at 18 years of age, when

gion, and it contains 14 coding exons.1,11 Prothrombin is synthesized

he had a traumatic thigh hemorrhage leading to compartment
syndrome necessitating surgical evacuation. No other history of
surgical interventions was reported. No gastrointestinal bleeds
were reported. However, a single episode of hematuria related
to strenuous exercise was documented. In the year before his
assessment, he noticed occurrence of more frequent soft-t issue
bleeding events while playing sports. He had been maintained on
tranexamic acid and FEIBA or prothrombin complex concentrate
as required. Physical examination was unremarkable. Coagulation
tests showed a prothrombin time of 19.9 seconds (normal range, 11-
15) and a partial thromboplastin time of 42 seconds (normal range,
20-29). Prothrombin activity was measured on two separate occasions using factor II–d eficient plasma (HemosIL, Instrumentation
Laboratory, Bedford, MA, USA) on an ACL Top 500 instrument
(Instrumentation Laboratory), and it was reported at 0.05 U/mL
(normal range, 0.50-2 .0). Activity of factors V, VII, VIII, IX, X, and
XI was reported within normal range. The proband’s sister and
one paternal uncle had a documented prothrombin deficiency, as
shown in the pedigree (Figure 1). Neither of the proband’s parents
had a documented history of bleeding, and it was unknown if they
were related by consanguinity.
Since the present report meets the criteria for a case review as
established by Western University’s Research Ethics Board, no formal approval was required. After obtaining consent from the patient

F I G U R E 1 Family pedigree
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in the liver and is usually present in plasma at concentrations of 1 to

analysis detected four genetic variations in the prothrombin gene

2 μM. The protein contains five functional domains: the propeptide

(Table 1). Two of those were benign polymorphisms with a reported

leader sequence, the γ-carboxyglutamic acid (Gla) domain, two Kringle

allele frequency of 20.5% and 59.3%. The other two variants have

areas, and the serine protease catalytic domain.11 Prothrombin is ac-

been reported at a very low frequency in normal control databases

tivated by factor Xa in the presence of phospholipids, calcium, and

(gnomAD over all allele frequency 0.001%; https://gnomad.broad

factor Va to form active α-thrombin, which cleaves fibrinogen into

institute.org/).

fibrin to form a blood clot. Thrombin is also involved in the activation

The first variant is a novel, missense, likely pathogenic variant

of other coagulation factors (V, VIII, and XIII) and has a role in plate-

(c.1147C>T) responsible for the substitution of amino acid arginine

let activation and aggregation.12 In addition, thrombin participates in

by tryptophan at the 383 amino acid position in the prothrombin

the anticoagulation process as it activates protein C. It plays a role

protein p.(Arg383Trp). This mutation results in changing one of the

in inflammation, cell proliferation, and tissue repair mechanisms.13

anion-binding recognition domains, namely, anion-binding exosite-I

For an unclear reason, prothrombin mutations are more prevalent

(at Arg20) (Figure 2). These sites are involved in interacting with sub-

in patients from a Latin/Hispanic origin (Puerto Rico, Spain, France,

strates, cofactors, and inhibitors and are critical for functions like

Prothrombin deficiency is classified into severe (when fac-

fibrinogen cleavage.14–18 Exosite-I has been shown to be important

tor level <5%), moderate (factor level 5%-10%), and mild (factor level

for recognition of substrates such as protease activator receptor-1,

etc.).

2,11

>10%).1 In patients with severe deficiency, the condition is always as-

factor V (FV), and factor VIII (FVIII); cofactors such as thrombomod-

sociated with a significant bleeding tendency, usually with prolonged

ulin and glycoprotein Ibα (GPIbα) and inhibitors such as heparin co-

postinjury bleeding and subcutaneous and muscle hematomas. This is

factor II. Therefore, considering the significance of these sites, an

similar to the presentation in the proband, though he technically has a

amino acid change at this residue may interfere with recognition and

moderate deficiency with a level of 5%.

interaction with substrate and/or binding proteins. This variant is

Until recently, dysprothrombinemia was thought of as a cause

predicted to be disease-causing by in silico pathogenicity prediction

for bleeding only. Although most patients with dysprothrombin-

tools (Mutation Taster (prob, 0.853), Polyphen2 (score, 1.00), SIFT

emia have been reported to exhibit a bleeding phenotype, some

(score, 0.02)). Although in silico assessment supports the pathogenic

cases have been reported in which the mutations led to thrombotic

nature of this variant, functional studies need to be performed to

episodes. 2 Therefore, dysprothrombinemia can be classified as a

evaluate the confirmed consequential impact of this variant at a bio-

hemorrhagic-thrombotic disorder, depending on the type of the mu-

chemical level.

tation present. 2

The second variant is a pathogenic deletion of two base pairs

Missense mutations (80%) are more common in the prothrom-

(c.1814_1815del), which changes the amino acid reading frame

bin gene compared to other types of variants including insertions/

after the 605 amino acid position and results in protein termination

1

deletions (10%) and nonsense (6%) and splice site variants (4%). As

after 13 amino acid residues. This deletion causes loss of three im-

prothrombin deficiency is a very rare bleeding disorder, identifica-

portant exosite-II positions falling in this region (Figure 2). Exosite-II

tion of new mutations is important to improve our understanding of

is known to interact with sulfated glycosaminoglycans present in

this condition.

heparin, a cofactor for the inhibition of thrombin by antithrom-

In this patient, we found two heterozygous genetic variants

bin. Functional and structural studies have shown that exosite-II is

in the prothrombin gene that occurred concurrently. The genetic

also involved in the recognition and cleavage of FV and FVIII and

TA B L E 1 Genetic variants identified in F2 gene in the patient
Variant (nucleotide
position) (NM_000506.3;
GRCh38)

Variant (amino acid
position)

Overall allele frequency reported
in GnomAD, a n (%)

In silico toolsb predicting
the variant as damaging

c.1814_1815del

p.(His605Argfs*13)

0.00001 (0.001)

-

ACMG #2 likely
pathogenic

c.1147C>T

p.(Arg383Trp)

0.00001 (0.001)

SIFT (score: 0.02)
Mutation Taster (prob,
0.853)
Polyphen2 (score, 1.00)

ACMG #3 variant of
unknown significance

c.494C>T

p.(Thr165Met)

0.205 (20.5)

None

ACMG #5 benign
polymorphism

c.423-7G>C

-

0.593 (59.3)

None

ACMG #5 benign
polymorphism

ACMG, American College of Medical Genetics and Genomics.7
a

GnomAd frequency (https://gnomad.broadinstitute.org/).

b

In silico tools: Polyphen2,8 SIFT,9 Mutation Taster.9

ACMG classification
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F I G U R E 2 Structure of prothrombin protein and effect of variants on protein. (A) This figure shows the domain architecture of the
prothrombin protein with location of the two variants (identified in our patient) in the B-chain region of the protein. (B) Amino acid sequence
of the B chain with highlighted (blue and green) exosite-I and II positions and pink boxes highlighting the exosite-I/II positions affected by
these two variants

also in the association of thrombin with GPIbα.14 The variant de-

R E L AT I O N S H I P D I S C LO S U R E

scribed here causes the loss of three of the five residues that form
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exosite-II, likely leading to significant impairment of the functions
of thrombin. This deletion (c.1814_1815del) has recently been re-
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ported in the heterozygous state in a patient with a coagulation
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disorder.

Collectively, these results indicate that the patient is heterozygous for two genetic variants in the prothrombin gene: one novel
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manuscript.

missense mutation predicted to be associated with the disease by in
silico assessment, and a second deletion mutation that causes loss of
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netic testing done in the proband’s parents or other family members
to confirm the compound heterozygous nature of these two vari-
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cates that these are likely inherited mutations and might be of value
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during investigation of other cases of prothrombin deficiency. This
case highlights the utility of molecular genetic testing in confirming
the diagnosis of patients with congenital prothrombin deficiency.
AC K N OW L E D G M E N T
We thank Dr. Ian Chin-Yee for his support, comments, and input.

REFERENCES
1. Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin
deficiency: an update. Semin Thromb Hemost. 2013;39(6):596–606.
2. Girolami A, Ferrari S, Cosi E, Girolami B, Lombardi AM. Congenital
prothrombin defects: they are not only associated with bleeding but

|

MANSORY et al.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

also with thrombosis: a new classification is needed. Hematology.
2018;23(2):105–110.
Peyvandi F, di Michele D, Bolton-maggs PHB, Lee CA, Tripodi A,
Srivastava A. Classification of rare bleeding disorders (RBDs) based
on the association between coagulant factor activity and clinical
bleeding severity. J Thromb Haemost. 2012;10(9):1938–1943.
Bafunno V, Bury L, Tiscia GL, et al. A novel congenital dysprothrombinemia leading to defective prothrombin maturation. Thromb Res.
2014;134(5):1135–1141.
Pasmant E, Dumont B, Lacapere JJ, Dautzenberg MD, Bezeaud A. A
severe neonatal presentation of factor II deficiency. Eur J Haematol.
2011;87(5):464–466.
Seki M, Koh K, Inoue T, et al. Prophylactic administration of prothrombin complex concentrates for congenital prothrombin deficiency with a novel frameshift mutation, prothrombin saitama.
Pediatr Blood Cancer. 2013;60(3):503–505.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the
interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet Med.
2015;17(5):405–424.
Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server
for predicting damaging missense mutations. Nat Methods.
2010;7(4):248–249.
Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web
server: predicting effects of amino acid substitutions on proteins.
Nucleic Acids Res. 2012;40(W1):W452-W457.
Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2:
mutation prediction for the deep-sequencing age. Nat Methods.
2014;11(4):361–362.
Girolami A, Santarossa L, Scarparo P, Candeo N, Girolami B. True
congenital prothrombin deficiency due to a “new” mutation in the
pre-propeptide (ARG-39 GLN). Acta Haematol. 2008;120:82–86.
Tamary H, Surrey S, Augustine J, Shalmon L, Schwartz E, Rappaport
EF. Molecular analysis of a compound heterozygote for hypoprothrombinemia and dysprothrombinemia (-G 7248/7249 and ARG
340 TRP). Blood Coagul Fibrinolysis. 1997;8(6):337–3 43. https://doi.
org/10.1097/00001721-199709000-0 0003.

5 of 5

13. Kankan SU, Jin Y, Miao Z, Cheng X, Yang L, Wang M. Phenotypic
and genetic analysis of dysprothrombinemia due to a novel homozygous mutation. Hematology. 2017;22(6):380–385. https://doi.
org/10.1080/10245332.2017.1287332.
14. Davie EW, Kulman JD. An overview of the structure and function of
thrombin. Semin Thromb Hemost. 2006;32(suppl 1):3–15.
15. Chahal G, Thorpe M, Hellman L. The importance of exosite interactions for substrate cleavage by human thrombin. PLoS One.
2015;10(6):e0129511.
16. Hall SW, Nagashima M, Zhao L, Morser J, Leung LL. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable
fibrinolysis inhibitor via specific and distinct domains. J Biol Chem.
1999;274(36):25510–25516.
17. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LL, Gibbs CS.
Functional mapping of the surface residues of human thrombin. J
Biol Chem. 1995;270(28):16854–16863.
18. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J.
The refined 1.9 A crystal structure of human alpha-thrombin:
interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J.
1989;8(11):3467–3 475.
19. Downes K, Megy K, Duarte D, et al. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet
disorders. Blood. 2019;134(23):2082–2091.

How to cite this article: Mansory EM, Bhai P, Stuart A,
Laudenbach L, Sadikovic B, Lazo-L angner A. A case of
congenital prothrombin deficiency with two concurrent
mutations in the prothrombin gene. Res Pract Thromb
Haemost. 2021;5:e12510. https://doi.org/10.1002/
rth2.12510

